Haya Therapeutics focuses on developing ribonucleic acid (RNA) therapies targeting the regulatory genome for serious health conditions. The company leverages its platform to create cell-state-modifying therapeutics that provide insights into long non-coding RNAs (lncRNAs), aiming to treat conditions such as cardiovascular disease and cancer. Haya Therapeutics primarily serves the healthcare sector, with a focus on developing treatments for rare and chronic diseases.